Here is a breakdown of major shareholders in Pacira BioSciences Inc (NASDAQ: PCRX)

Pacira BioSciences Inc (NASDAQ: PCRX) is -17.90% lower on its value in year-to-date trading and has touched a low of $25.93 and a high of $48.60 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PCRX stock was last observed hovering at around $28.49 in the last trading session, with the day’s loss setting it -0.79%.

Currently trading at $27.70, the stock is -13.11% and -11.18% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.32 million and changing -2.77% at the moment leaves the stock -19.88% off its SMA200. PCRX registered -33.41% loss for a year compared to 6-month loss of -27.22%. The firm has a 50-day simple moving average (SMA 50) of $2.47 and a 200-day simple moving average (SMA200) of $13.50.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

The stock witnessed a -20.24% gain in the last 1 month and extending the period to 3 months gives it a -8.52%, and is -12.82% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.37% over the week and 3.81% over the month.

Pacira BioSciences Inc (PCRX) has around 715 employees, a market worth around $1.29B and $665.69M in sales. Current P/E ratio is 355.58 and Fwd P/E is 8.06. Profit margin for the company is 1.05%. Distance from 52-week low is 6.83% and -43.00% from its 52-week high. The company has generated returns on investments over the last 12 months (0.50%).

Pacira BioSciences Inc quarterly earnings per share for the current quarter are estimated at $0.88 with sales reaching $181.22M over the same period.The EPS is expected to grow by 12.13% this year, but quarterly earnings will post 1.90% year-over-year. Quarterly sales are estimated to grow 5.40% in year-over-year returns.

351 institutions hold shares in Pacira BioSciences Inc (PCRX), with institutional investors hold 106.46% of the company’s shares. The shares outstanding are 45.93M, and float is at 45.05M with Short Float at 8.27%. Institutions hold 104.96% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 7.48 million shares valued at $299.78 million. The investor’s holdings represent 16.12% of the PCRX Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 4.95 million shares valued at $198.44 million to account for 10.67% of the shares outstanding. The other top investors are State Street Corporation which holds 1.72 million shares representing 3.70% and valued at over $68.85 million, while Frontier Capital Management Company LLC holds 3.63% of the shares totaling 1.69 million with a market value of $67.53 million.

Pacira BioSciences Inc (PCRX) Insider Activity

A total of 0 insider transactions have happened at Pacira BioSciences Inc (PCRX) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by WINSTON ROY, the company’s Chief Medical Officer. SEC filings show that WINSTON ROY sold 509 shares of the company’s common stock on Aug 02 at a price of $34.88 per share for a total of $17751.0. Following the sale, the insider now owns 52440.0 shares.

Pacira BioSciences Inc disclosed in a document filed with the SEC on Jul 05 that Riker Lauren Bullaro (Senior Vice President, Finance) sold a total of 643 shares of the company’s common stock. The trade occurred on Jul 05 and was made at $38.91 per share for $25019.0. Following the transaction, the insider now directly holds 22687.0 shares of the PCRX stock.

Still, SEC filings show that on Jun 14, Riker Lauren Bullaro (Senior Vice President, Finance) disposed off 6,366 shares at an average price of $38.42 for $0.24 million. The insider now directly holds 22,687 shares of Pacira BioSciences Inc (PCRX).

Pacira BioSciences Inc (PCRX): Who are the competitors?

One of the company’s main competitors (and peers) include Cencora Inc. (COR) that is trading 44.83% up over the past 12 months.Societal CDMO Inc. (SCTL) lies in the list of competitors of the Pacira BioSciences Inc and is -68.27% lower over the same period from PCRXDurect Corp. (DRRX) is -85.95% down on the 1-year trading charts.